Scottsdale – Allergan, Inc., today announced the U.S. FDA’s approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers.  Allergan’s new JUVÉDERM® formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds that appear around the nose and mouth.  JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment and number-one selling hyaluronic acid dermal filler (Source: Businesswire).